



General Certificate of Conformity

Pursuant to The Consumer Product Safety Improvement Act (CPSIA), The Takeda Company certifies that products subject to the Poison Prevention Packaging Act (PPPA) comply with all relevant rules, bans and/or standards enforced by the Consumer Product Safety Commission (CPSC). The products listed in this certificate require child resistant (CR) packaging and testing.

Product Description: (Name, Package Type, Count, Dosage, NDC)	Uloric (febuxostat) 7ct bottle, 40mg tablet NDC 64764-918-00 7ct bottle, 80mg tablet NDC 64764-677-00 30ct bottle, 40mg tablet NDC 64764-918-30 30ct bottle, 80mg tablet NDC 64764-677-30
The regulation(s), rule(s), ban(s), and or standard(s) to which this product is being certified:	16 CFR <i>Commercial Practices</i> > Chapter II > Subchapter E > Part 1700 <i>Poison Prevention Packaging</i> § 1700.14 (a) (10) Substances requiring special packaging § 1700.15 Poison prevention packaging standards § 1700.20 Testing procedure for special packaging
Identification of the U.S. importer or domestic manufacturer certifying compliance of the product.:	Takeda Pharmaceuticals U.S.A., Inc. One Takeda Parkway Deerfield, IL 60015 USA
Contact information for the individual maintaining records of test results:	Director, Packaging Technology Takeda Pharmaceuticals U.S.A., Inc. One Takeda Parkway Deerfield, IL 60015 USA
Date and place where this product was tested for compliance With the regulation(s), rule(s), ban(s) and or standard(s) cited above and test report(s) on which certification is based:	Drug Plastics & Glass Co, Inc. 1 Bottle Drive Boyertown, PA 19512 USA Test Id: DPG11-12A October 19 - October 27 2011 Test Id: DPG 11-12C November 3- November 18 2011
Third party laboratory that conducted testing upon which this certification is based:	Bird Dog Marketing Group LLC 3125 Nolt Road Lancaster, PA 17601 USA Contact: Mark D. Perkins (717) 615 9022 David Hipple (717) 475 9751

Effective